Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.

Watanabe T, Hotta C, Koizumi S, Miyashita K, Nakabayashi J, Kurotaki D, Sato GR, Yamamoto M, Nakazawa M, Fujita H, Sakai R, Fujisawa S, Nishiyama A, Ikezawa Z, Aihara M, Ishigatsubo Y, Tamura T.

Cancer Res. 2013 Nov 15;73(22):6642-53. doi: 10.1158/0008-5472.CAN-13-0802.

2.

Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.

Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF.

Blood. 2009 May 7;113(19):4681-9. doi: 10.1182/blood-2008-05-156471. Epub 2009 Feb 27.

3.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

4.

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.

Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.

Cancer Res. 2007 Jun 1;67(11):5489-97.

5.
6.

BCR/ABL promotes dendritic cell-mediated natural killer cell activation.

Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, Zitvogel L.

Cancer Res. 2005 Jul 15;65(14):6409-17.

7.

Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.

Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP.

J Immunol. 2003 Aug 15;171(4):1780-91.

8.

HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.

Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, Hirai H, Fujita S.

Blood. 2001 Sep 1;98(5):1498-505.

9.

Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.

He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E.

Cancer Immunol Immunother. 2001 Mar;50(1):31-40.

PMID:
11315508
10.

BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.

Grünebach F, Mirakaj V, Mirakaj V, Müller MR, Brümmendorf T, Brossart P.

Cancer Res. 2006 Jun 1;66(11):5892-900.

12.

Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.

Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Cattelani S, Donato NJ, Calabretta B.

Blood. 2006 Aug 15;108(4):1353-62. Epub 2006 May 2.

13.

Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.

Casnici C, Volpe G, Crotta K, Lattuada D, Saglio G, Marelli O.

J Immunother. 2012 May;35(4):321-8. doi: 10.1097/CJI.0b013e3182562d37.

PMID:
22495389
14.
15.

Chronic myelogenous leukemia: molecular and cellular aspects.

Pasternak G, Hochhaus A, Schultheis B, Hehlmann R.

J Cancer Res Clin Oncol. 1998;124(12):643-60. Review.

PMID:
9879825
16.

A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia.

He Q, Dong J, Zhen H, Ying Y, Zhang J, Li Q, Li B, Zhou Y.

Leuk Res. 2011 Aug;35(8):1074-9. doi: 10.1016/j.leukres.2010.11.012. Epub 2010 Dec 15.

PMID:
21163528
17.

A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.

Zorn E, Orsini E, Wu CJ, Stein B, Chillemi A, Canning C, Alyea EP, Soiffer RJ, Ritz J.

Transplantation. 2001 Apr 27;71(8):1131-7.

PMID:
11374415
18.
19.

Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D.

Blood. 1998 Nov 15;92(10):3780-92.

20.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Wongboonma W, Thongnoppakhun W, Auewarakul CU.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

PMID:
22314255

Supplemental Content

Support Center